Back to All Combinations

KRAS G13D

Prognosis
7.00% Prevalence Level 2A RAS Pathway
Genes Involved
KRAS
Treatment Implications

Standard chemotherapy backbone. Anti-EGFR controversy: Retrospective data (De Roock 2010, PMID: 20619739) suggested possible cetuximab sensitivity, but ICECREAM study did not confirm benefit. NOT recommended for anti-EGFR outside trials. If HER2 co-amplified, consider T-DXd.

Recommended Treatments
FOLFOX/FOLFIRI + Bevacizumab
FOLFOXIRI + Bevacizumab
TAS-102 + Bevacizumab (third-line)
Treatments to Avoid
Anti-EGFR
Study References

De Roock 2010 (PMID: 20619739), ICECREAM study

Key Statistics
7.00%
Prevalence in CRC
No
Targetable
Clinical Notes
KRAS G13D represents ~7% of mCRC. Prognosis intermediate between KRAS WT and G12 mutations. Historical controversy about cetuximab sensitivity not confirmed prospectively. If HER2 co-amplified, consider T-DXd (DESTINY-CRC02).
Information

Category: RAS Pathway

Evidence Level: Level 2A

Last Updated: Dec 21, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.